Testing a new bladder cancer treatment for recurring tumors

Plain-English translation of NCT06637423 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called that is delivered directly into the bladder to treat bladder cancer that keeps recurring. The study will check how safe this medication is, how well patients tolerate it, and find the best dose to use in future studies. Researchers want to understand if the treatment can help people whose bladder cancer has come back after previous treatment.

People with intermediate-risk non-muscle invasive bladder cancer often have their cancer come back, even after standard treatments like intravesical therapy (medicine placed directly in the bladder). This trial exists to test whether this new medication could offer a better option for patients whose cancer keeps recurring or who didn't respond well to previous bladder treatments.

Do you qualify?

You likely qualify if…

you have been diagnosed with low-grade non-muscle invasive bladder cancer that has come back
your doctor saw a visible tumor in your bladder within the past 12 weeks
your cancer meets intermediate-risk criteria, such as multiple tumors, early recurrence, a large single tumor, or failure of prior bladder treatment
you have a good enough overall health status (Eastern Cooperative Oncology Group performance status of 0 to 2)
you are able to hold urine in your bladder for 1 to 2 hours during treatment

You likely don't qualify if…

you have newly diagnosed bladder cancer (not yet treated)
you have been diagnosed with high-grade bladder cancer, muscle-invasive bladder cancer, or cancer that has spread beyond the bladder
you have severe eye conditions such as severe dry eye syndrome or severe corneal disease that prevents healing
you have active inflammatory bowel disease requiring immune-suppressing medications or a history of conditions like Crohn's disease or ulcerative colitis
you have uncontrolled heart or blood vessel disease, or a history of severe lung inflammation that required steroids

What participation looks like

If you join this trial, you will receive the medication delivered directly into your bladder over a 6-week treatment period. You will have regular visits with your research team so they can monitor your safety, check for side effects, and see how your bladder cancer is responding to the treatment. The study involves 32 participants total, and the exact number and timing of your visits will be discussed with the research team.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(13 sites)

United States

Michael G Oefelein Clinical Trials ( Site 0053), Bakersfield, California

Moffitt Cancer Center ( Site 0057), Tampa, Florida

Northwestern University ( Site 0051), Chicago, Illinois

Johns Hopkins University ( Site 0055), Baltimore, Maryland

Canada

Princess Margaret Cancer Centre ( Site 0003), Toronto, Ontario